LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 2,032,704 shares, a decline of 16.6% from the January 29th total of 2,436,767 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average daily volume of 676,965 shares, the days-to-cover ratio is presently 3.0 days. Based on an average daily volume of 676,965 shares, the days-to-cover ratio is presently 3.0 days. Approximately 3.7% of the shares of the stock are short sold.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. Primecap Management Co. CA raised its holdings in shares of LivaNova by 0.7% in the 2nd quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after purchasing an additional 32,942 shares during the period. Millennium Management LLC increased its position in LivaNova by 17.3% during the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after purchasing an additional 514,268 shares in the last quarter. Artisan Partners Limited Partnership increased its position in LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP raised its holdings in LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the period. Finally, Vanguard Group Inc. raised its holdings in LivaNova by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after buying an additional 34,812 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. Barclays increased their price target on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research note on Wednesday, February 25th. Robert W. Baird set a $75.00 price objective on LivaNova in a research report on Tuesday, December 16th. Finally, Mizuho raised their price target on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Trading Down 4.6%

LivaNova stock traded down $3.17 during trading on Wednesday, hitting $65.26. The company’s stock had a trading volume of 1,206,544 shares, compared to its average volume of 772,640. The stock’s fifty day moving average is $64.99 and its 200 day moving average is $59.36. LivaNova has a 1-year low of $32.48 and a 1-year high of $71.92. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of -14.63 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. The business had revenue of $360.86 million for the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period last year, the company earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities research analysts predict that LivaNova will post 2.85 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.